Roche Announces Thomas Schinecker as New President of 454 Life Sciences
454 Life Sciences, a center of excellence of Roche’s business unit Applied Science, announced that effective August 1, 2011, Dr. Thomas Schinecker is appointed Lifecycle Leader for Sequencing and President of 454 Life Sciences, Inc., in Branford, Connecticut, USA, reporting to Robert Yates, Head of Applied Science.
Dr. Schinecker is currently the Diagnostics General Manager of Sweden, located in Bromma, a suburb of Stockholm. Dr. Schinecker’s extensive background and experience of over eight years at Roche will be instrumental in guiding 454 Life Sciences into the next generation of pyrosequencing. Dr. Schinecker holds a PhD in oncology, studying at the New York University. He then excelled in several leadership positions in the Sales & Marketing organization of Roche Diagnostics Austria, starting his career at Roche in the Perspectives Program in 2003. With his success in several key management positions within Roche Diagnostics, Dr. Schinecker brings the required organizational and operating skills to 454 Life Sciences’ highly innovative and accurate long sequence read technology. 454 Sequencing Systems are used productively by large numbers of life science researchers in cancer, infectious disease, immunogenetics, drug discovery, agriculture and other disciplines, resulting in more than 1,000 peer-reviewed publications.
454 Life Sciences, a center of excellence of Roche’s business unit Applied Science, announced that effective August 1, 2011, Dr. Thomas Schinecker is appointed Lifecycle Leader for Sequencing and President of 454 Life Sciences, Inc., in Branford, Connecticut, USA, reporting to Robert Yates ... more
The deadly E. coli O104 strain that has killed dozens and hospitalized thousands across Europe has been sequenced using 454 Life Sciences’ benchtop GS Junior sequencing system to generate the “most accurate and detailed genetic analysis to date” of this particularly virulent strain. The seq ... more
RainDance Technologies, Inc., and 454 Life Sciences, a Roche Company, announced collaboration for the development and commercialization of a targeted next-generation sequencing (NGS) solution for simple and cost-effective investigation of drug absorption, distribution, metabolism, and excr ... more
Evotec AG was updated today by its partner Roche on the initial results of the Phase IIb trial with Sembragiline (RG1577, EVT302), a MAO-B inhibitor for the treatment of Alzheimer's disease ("AD"). In this study, Sembragiline failed to demonstrate benefit on the primary endpoint (Alzheimer' ... more
Roche announced it has acquired CAPP Medical, a genomics research company founded by Stanford University oncologists and industry veterans, to advance the development of technology for cancer screening and monitoring through the detection of circulating tumor DNA (ctDNA) in blood. CAPP Med ... more
Roche announced the acquisition of Signature Diagnostics AG, a privately held company based in Potsdam, Germany. Signature is a translational oncology and genomics company that develops large blood plasma and tissue biobanks in multiple cancers, including colorectal and lung, which are cons ... more
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche i ... more
The three winners of the first Roche Pharma Research & Development (pRED) Oncology Awards in the field of ‘Novel Highly tumour-selective Membrane Targets for Antibody-based Cancer Therapy’ have been selected.
Krishna Chaitanya of the Oncological Institute at the University Hospital Zurich r ... more
In a newly created award, pRED`s Discovery Oncology unit of Roche (RHHBY) in Penzberg, Germany invites European researchers to submit abstracts which describe their scientific work in the field of tumor-selective membrane targets for antibody-based cancer therapy. The award aims to honor an ... more
Roche and SynenTec announced that Roche will transfer its Cellavista business to SynenTec, the German company which is the original inventor of the Cellavista System. This agreement was made as a result of the Roche Applied Science decision to focus its business, and guarantees future optim ... more
Roche’s xCELLigence System RTCA HT Instrument performs real-time impedance-based label-free measurement of cell behavior for high throughput applications. It´s technology is compatible with workflows carrying out automated screening using the 384-well culture plate format more
Roche’s xCELLigence Cardio Instrument is a medium-throughput cell analyzer using impedance recording to monitor cardiac beating and cellular events in real time. The instrument features high resolution detection rate and frequency measurement technology driven by dedicated software. Unlike ... more
Medicinal Genomics sequenced the entire genomes of Cannabis sativa and Cannabis indica, two strains of the therapeutic plant. These largest known Cannabis genome assemblies comprise over 131 billion bases of sequence and will advance research on the more